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ABSTRACT
Atherosclerosis is a cardiovascular disease characterized by the hardening of arteries
through the formation of cholesterol plaques. Cyclodextrins have the potential to treat
atherosclerosis by shrinking plaques. These cyclic oligosaccharides are known to
make complexes with cholesterol and have potentially dangerous side effects such
as cytotoxicity and gut microbiome changes. This study looked for potential negative
effects of cyclodextrins and cholesterol on gut bacteria. It was hypothesized that
Bacteroides vulgatus will have decreased growth when grown in broth with cholesterol.
In contrast, it was hypothesized that Clostridium bolteae will have decreased growth
when grown in broth with cyclodextrins. Due to the fact that these bacteria are
anaerobic, Clostridium bolteae and Bacteroides vulgatus, were grown using Gifu
Anaerobic Broth under CO². Data was collected by using a spectrophotometer to
measure changes in bacterial growth throughout the growth cycle. Each bacteria was
treated with one of three chemicals at one of three concentrations to make a total of 9
different conditions. α-cyclodextrin, 2-hydroxypropyl-β-cyclodextrin, and cholesterol
were used to treat the bacteria at concentrations of 1 mM, 10 mM, and 100 mM. The
slopes of the log phase of bacterial growth were compared using a two tailed t-test with
α = 0.05. Growth of Clostridium bolteae was significantly inhibited for most of the
cyclodextrin treatments and all the cholesterol concentrations. Bacteroides vulgatus
growth was inhibited by 100 mM concentrations of cholesterol and α-cyclodextrins.
Interestingly, Bacteroides vulgatus growth was significantly increased when grown
with 1 mM and 10 mM concentrations of cholesterol. These results demonstrate that
cyclodextrins are associated with inhibited growth for these two prototypic gram
negative and gram positive gut bacteria. Expansion of this study to other gut bacteria
is key for a deeper understanding of the impact that cyclodextrins would have on the
gut microbiome as a whole.
INTRODUCTION
Atherosclerosis is a cardiovascular disease with one of the highest mortality rates
in the world. It is characterized by the formation of cholesterol-filled plaques that
are chronically inflamed and continue to develop until they occlude the artery or
break off causing a stroke or heart attack. Statins are the current standard treatment
for atherosclerosis and for the precursor to atherosclerosis, high cholesterol. These
drugs lower the levels of unhealthy lipoproteins to slow the progression of plaques
(Lusis 2000). However, there remains a gap in medical treatment for a way to reduce
inflammation and remove cholesterol from plaques to lower the risk for heart attacks
and strokes. Cyclodextrins are oligosaccharides that have been found to regress
atherosclerosis through the potential mechanism of decreasing inflammation and
shrinking plaques by extracting cholesterol from membranes (Zimmer et al. 2016).
Using a computer simulation, it was demonstrated that the mechanism for this removal
may be that cyclodextrins form dimers to pull out cholesterol molecules, forming 2:1
cyclodextrin-cholesterol complexes (LóPez et al. 2011).
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The most widely studied cyclodextrin, 2-Hydroxypropyl-β-cyclodextrin (HPβCD),
has been shown to solubilize cholesterol and have minimal cytotoxic effects on human
cells (Szente et al. 2018). Indeed, HPβCD was studied in clinical trials for the treatment
of Niemann-Pick C, a fatal hereditary disease that can be characterized by the buildup
of cholesterol in lysosomes (Singhal et al. 2018). Theoretically, HPβCD promotes the
removal of cholesterol from these lysosomes in a similar way to atherosclerotic plaque
regression. HPβCD is a frontrunner in atherosclerosis research because of its success
in Niemann-Pick C clinical trials (Singhal et al. 2018). Another commonly studied
cyclodextrin for atherosclerosis treatment is α-cyclodextrin (αCD). αCD was found to
inhibit inflammatory pathways better than HPβCD (Pilely et al. 2019). In one study,
αCD was also found to decrease obesity by improving lipid metabolism in mice (Nihei
et al. 2018).
A study with human erythrocytes and a Caco-2 cell line showed that αCD was cytotoxic
to these cells; however, once a complex was formed with cholesterol, the cytotoxicity
of αCD decreased. This same study proposed that αCD could also form complexes
with phospholipids (Roka et al. 2015). The mechanism for cyclodextrin cytotoxicity
has not been confirmed but is speculated to be related to the removal of cholesterol
from membranes. However, the direct effect of cyclodextrins on the cytotoxicity of gut
bacteria has not been assessed.
The microbiome has become the focus of research for a variety of diseases because
of its connectivity to human health. Atherosclerosis is no exception; distinct changes
in the human gut microbiome have been noted in patients with atherosclerosis (Jie et
al. 2017). Interestingly, changes in gut microbiomes of mice with atherosclerosis have
also been studied. These mice were fed high fat diets (HFD), which affected their gut
microbiome; then, other mice were fed the same diet with αCD and had another large
change in bacterial composition. There was a decrease in the Bacteroides genus in
mice fed a HFD, but they rebounded in mice that were treated with αCD along with
their HFD. On the other hand, Clostridium cluster XIVa was increased in mice that
were fed a HFD but drastically decreased when αCD was added (Nihei et al. 2018).
These results indicate that αCD and cholesterol are impacting the growth of the gut
microbiome. Cyclodextrins are not absorbed but are fermented by the gut bacteria, as
evidenced by their absence in fecal analysis, suggesting direct contact between the
bacteria and these molecules (Amar et al. 2016). Analysis of these changes of bacteria
found that inflammation increased when certain strains of bacteria were decreased in
vivo (Yoshida et al. 2018). Clostridium bolteae and Bacteroides vulgatus are anaerobic
bacteria found in the human gut microbiome (Maier et al. 2018). Each has its own
unique properties and benefits for overall health. B. vulgatus was studied specifically
in mice with induced atherosclerosis and was found to have anti-inflammatory effects
(Yoshida et al. 2018). This is an important piece of information because the genus,
Bacteroides, was found to be less prevalent in the gut of mice that were fed a high fat
diet. On the other hand, C. bolteae is a member of Clostridium cluster XIVa, which
was found to be increased in mice that were being fed a high fat diet (Nihei et al.
2018). Clostridium bacteria have been found to both be proinflammatory and to help
regulate inflammation depending on the species (Barnes and Powrie 2011). A healthy
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balance of gut bacteria is key to a healthy host. It is vitally important to be aware
of how different treatments affect microbiome health and to ensure that they are as
beneficial as possible and do not have unforeseen side effects. It is important to see
if these bacteria are being negatively affected by cyclodextrin treatment. The human
microbiome plays an important role in atherosclerosis, so the health of these bacteria is
vital and should be considered when testing possible treatments.

and time of each sample were recorded to create the growth curve. Samples were tested
at these times: 1 hr, 2 hr, 3 hr, 4 hr, 5 hr, 6 hr, 8 hr, 10 hr. This was found to accurately
capture the growth curve of B. vulgatus and was used for the experimental trials as
well. αCD, HPβCD, and cholesterol were all tested individually at three different
concentrations: 1mM, 10mM, and 100mM. Three trials were run for each treatment to
limit random error.

Despite the promising data suggesting that cyclodextrins may help to regress
atherosclerotic plaques, the specific, direct effects of cyclodextrins on the gut bacteria
B. vulgatus and C. bolteae are not clear. In vivo studies are plagued by complex
variables that are difficult to control. Isolating individual bacteria for testing can negate
these variables. B. vulgatus was decreased in both human and mouse studies when
under atherosclerotic conditions, whereas C. bolteae was decreased when αCD was
introduced into the diet of the mice. This leads to the central questions being addressed
in this current proposal: what are the effects of cyclodextrins and cholesterol on these
bacterial species? Based on the changes that occur in vivo the following hypotheses
were developed:

Clostridium bolteae was rehydrated from a freeze-dried stock in GAM broth in a shaking
water bath, and then frozen stocks were made as previously stated. All methods were
the same for C. bolteae apart from the times that samples were taken. The absorbances
were recorded at these times: 0.5 hr, 1 hr, 2 hr, 2.5 hr, 3 hr, 4 hr, 5 hr, 6 hr.

1. Bacteroides vulgatus will have decreased growth when grown in broth with
cholesterol.
2. Clostridium bolteae will have decreased growth when grown in broth with
cyclodextrins.
METHODS
Materials
Bacteria were purchased from ATCC, Clostridium bolteae and Bacteroides vulgatus.
Cyclodextrins were purchased from Fischer Scientific, αCD 98% (100 g) and HPβCD
(100 g). 92.5% cholesterol was purchased from Sigma Aldrich. Gifu Anerobic Broth
was purchased from Thomas Scientific. Olivet Nazarene University provided 12mL
Falcon tubes and 1 mL, 5 mL, and 10 mL sterile single use pipets.
Equipment
All equipment was provided by Olivet Nazarene University: UV/VIS spectrophotometer,
shaking water bath incubator and a carbon dioxide gas tank.

Growth curves were analyzed by measuring the slope of the log phase growth where
the linear upward slope was found. The slopes of each trial were compared to the slopes
of the control with a two-tailed t-test. The data is displayed as means +/- standard
deviation and P values of less than 0.05 will be used as the threshold for determining
statistical significance. Though more rigorous statistical analysis is needed to more
accurately understand the data, this was the method developed within the limited
timespan.
RESULTS
Bacteroides vulgatus has a standard sigmoidal growth curve with a linear growth
period. αCD treatments for Bacteroides vulgatus growth was not affected by αCD at
lower concentrations. However, Bacteroides vulgatus growth was completely inhibited
by 100 mM αCD (Figure 1).
Bacteroides vulgatus cultured with 1 mM and 10 mM cholesterol exhibited a significant
increase in growth rate. The 100 mM concentrations of cholesterol and αCD completely
inhibited growth (Figure 2). These three treatments, along with the 100 mM αCD, are
all the statistically significant treatments for Bacteroides vulgatus. Growth curves for
HPβCD treatments are not depicted due to their lack of significant growth inhibition.
All HPβCD and all cholesterol treatments, along with 1 mM and 100 mM αCD, were
shown to inhibit Clostridium bolteae growth (Figure 3).

Methods
Bacteroides vulgatus was revived from frozen stock in Gifu Anaerobic Broth (GAM)
in a shaking water incubator. Growth curves were determined using the same procedure
for each trial: two bacterial falcon tubes were made containing 10 mL of fresh broth
and 0.5 mL of bacteria-containing broth. These tubes were made anaerobic by filling
them with carbon dioxide gas then immediately sealing them. 1 mL samples were
taken every hour for 12 hours, alternating between two tubes. Every time a tube was
opened it was filled with carbon dioxide again. The absorbance of these samples was
immediately measured at 560 nm using the UV/Vis spectrophotometer. The absorbance
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Figure 2. All the cholesterol treatments for Bacteroides vulgatus affect growth. Bacteroides vulgatus
was grown in GAM broth under anaerobic conditions with appropriate treatment mixed into broth. All
three treatments were statistically significant. t-tests were run to compare the slopes. Statistical significance
was defined as P < 0.05.

Figure 1. 100mM alpha cyclodextrin (αCD) inhibits Bacteroides vulgatus growth. The data displayed
were from mean values with error bars showing 1 standard deviation. Top graph depicts full growth
curve for Bacteroides vulgatus under all three treatments of αCD along with a control curve. Bottom
graph depicts cropped graphs to display the linear growth segment that was analyzed. These two graphs
display the same set of data. Bacteroides vulgatus was grown in GAM broth under anaerobic conditions
with appropriate treatment mixed into broth. The line of best fit was found for this segment. Slopes were
compared using a two-tailed t-test.
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Table 1 includes all the mean slope values with one standard deviation along with their
corresponding p values. P < 0.05 indicates statistical significance. There are twelve
statistically significant treatments between both bacteria tested. 1 mM, 10 mM and 100
mM concentrations of cholesterol and HPβCD showed statistically significant changes
in growth for Clostridium bolteae. 1 mM and 100 mM concentrations of αCD also
show p values of less than 0.05 for Clostridium bolteae. Bacteroides vulgatus showed
statistically significant changes in growth for 100 mM αCD and 1 mM, 10 mM, and
100 mM concentrations of cholesterol.

DISCUSSION

Figure 3. Eight out of nine treatments inhibit Clostridium bolteae growth. Top graph depicts
cyclodextrin treatments that inhibited Clostridium bolteae growth. Bottom graph depicts all cholesterol
treatments that inhibited Clostridium bolteae growth. Clostridium bolteae was grown in GAM broth
under anaerobic conditions with appropriate treatment mixed into broth. T-tests were run to compare
the slopes of the log phase and significance was defined as P < 0.05. All the concentrations shown were
inhibiting growth.
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This study sought to test two hypotheses: Bacteroides vulgatus will have decreased
growth when grown in broth with cholesterol, and Clostridium bolteae will have
decreased growth when grown in broth with cyclodextrins. Bacteroides vulgatus was
treated with nine different treatments. Of those nine treatments, four were statistically
significant (Table 1). 2-hydroxypropyl-β-cyclodextrin (HPβCD) is specifically
designed to be less toxic; the added hydroxypropyl groups decrease the affinity for
cholesterol, which has been shown to lower the toxicity (Szente et al. 2018). The data
for Bacteroides vulgatus is consistent with this purpose; even at 100 mM HPβCD, the
growth of this bacteria was not significantly inhibited. The toxic effects of unsubstituted
αCD can be seen in the treatment: when Bacteroides vulgatus was treated with 100
mM αCD, it was completely inhibited. However, this inhibition is not present at lower
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concentrations, suggesting a tipping point of cholesterol regulation for this species.
This is consistent with the previous study that α-cyclodextrin is slightly more toxic
than 2-hydroxypropyl-β-cyclodextrin. Both are still being studied as treatments for
atherosclerosis (Szente et al. 2018).
The hypothesis for Bacteroides vulgatus was that it would be inhibited when grown
in broths with cholesterol. This was based on a study by Jie et al. (2017) on patients
with atherosclerosis where their gut microbiome was analyzed for consistent changes
occurring in most atherosclerotic patients. The Bacteroides genus was decreased in
general, and it was suspected that these bacteria grow poorly under high fat conditions
that are usually associated with atherosclerosis. This was supported by the study
done by Nihei et al. on mice. Cholesterol was tested because of the limited ability to
replicate a high fat diet in vitro. This hypothesis is supported at 100 mM cholesterol
concentrations where Bacteroides vulgatus was significantly inhibited. Surprisingly,
1 mM and 10 mM concentrations of cholesterol significantly increased the growth of
Bacteroides vulgatus. There was more increased growth in the 1 mM than the 10 mM.
Then, at 100 mM, the growth becomes inhibited. The mechanism for this increased
growth in unknown. The data presented for the lower concentrations of cholesterol
contradict the predicted trend. This may be due to the fact that the studies were using
high fat diets, whereas this study looked at cholesterol alone (Jie et al. 2017; Nihei
et al. 2018). There is more research to be done to see where the concentrations of
cholesterol transition from beneficial to harmful. There is also a need for this study to
be replicated to see if similar results are being found. This study focused on only one
species in the Bacteroides genus, and it would be beneficial to learn if the entire genus
reacts similarly to these conditions. It is difficult to draw large conclusions based on
a study of a specific bacteria when the gut microbiome is a diverse population. The
diversity of the microbiome is key to its function, and a possible unwanted side effect
of cyclodextrins could be the destruction of that diversity.

the hypothesis that Clostridium bolteae is specifically inhibited by cyclodextrins,
even the one deemed less toxic. Clostridium bolteae also showed significant growth
inhibition for cholesterol at all concentrations. In Jie’s study on atherosclerotic
patients, the Clostridium genus was increased in these patients, unlike the Bacteroides
genus. There is not research supporting the decreased growth of Clostridium bolteae
in cholesterol. Bacteroides vulgatus is not entirely representative of the Bacteroides
genus and the Clostridium genus is even more varied (Barnes and Powrie 2011). There
is a need for further research on other members of the Clostridium genus to explain the
increase of the population under atherosclerotic conditions. There is a possibility that
Clostridium bolteae decreases, but other species thrive. This possibility points to the
importance of expanding the study to include a large variety of species of gut bacteria.
CONCLUSION
The results from these two gut bacteria species show that cyclodextrins can inhibit
growth of gut bacteria, although further research should be done to see if this inhibition
will be universally detrimental to the gut microbiome. The results indicate that there
is some dose dependence for the inhibition. Further statistical analysis with a more
rigorous method should be used to gain a clearer picture of the data. The health of gut
microbiome composition should be monitored in future clinical research. Further research is needed to fully understand the general impact that cyclodextrins would have
on the gut microbiome. This study was limited by the small number of bacteria tested
along with limited concentration range. The maintenance of an anerobic environment
was difficult to control and though every attempt was made to control the environment,
oxygen contamination could contribute to the results. Overall, this research supports
cyclodextrins having adverse side effects on gut bacteria while raising new questions
for future work.

Clostridium bolteae was treated with the same nine treatments as Bacteroides vulgatus.
This bacteria was more susceptible to inhibition; it was significantly inhibited by eight
of the nine treatments. Interestingly, the only treatment that did not show any significant
changes in growth was 10 mM αCD. All other data was consistent with previous
studies. Similar to Bacteroides vulgatus, 100 mM concentrations of cholesterol and
αCD inhibited growth significantly. The slopes are nearly zero for these two treatments
as it is seen in Table 1. The lower the concentrations, the less significant the growth
inhibition. It is interesting that 100 mM αCD has a slope of nearly zero, whereas 100
mM HPβCD still shows growth. This is consistent with the idea presented earlier that
HPβCD is less toxic than αCD (Szente et al. 2018).
The hypothesis for Clostridium bolteae was that there would be inhibited growth when
grown in broth with cyclodextrins. This is supported by results from a study on mice
that were treated with cyclodextrins, and they had decreased Clostridium populations
(Nihei et al. 2018). In general, this is supported with the data from this study, except for
10 mM αCD. It is key to note that Bacteroides vulgatus was unaffected by HPβCD but
Clostridium bolteae had significant growth inhibition at all concentrations. This supports
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